{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013195","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.681441+00:00","generated_at":"2026-05-15T04:43:07.262080+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vaxart appoints Dr. James Breitmeyer to board of directors","bullets":["Dr. James Breitmeyer appointed to Vaxart Board effective April 23, 2026.","Brings over 35 years biopharma experience; led programs yielding 8 FDA product approvals.","Currently CEO and director of Altay Therapeutics; formerly President & CEO of Oncternal Therapeutics (2016-2025).","Prior roles include President of Bavarian Nordic (cancer/infectious disease vaccines) and senior clinical leadership at Eli Lilly and Cadence.","Will receive standard non-employee director cash and equity compensation under Vaxart's program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013195","json":"https://secwatch.observer/filing/0001437749-26-013195.json","markdown":"https://secwatch.observer/filing/0001437749-26-013195.md","text":"https://secwatch.observer/filing/0001437749-26-013195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774926013195/0001437749-26-013195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774926013195/vxrt20260423_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:43:07.262080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}